These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6255698)

  • 1. ESR spectra of normal human serum after treatment with complement activating agents.
    Bartolotta A; Brai M; Messina M; Indovina PL
    Z Naturforsch C Biosci; 1980; 35(9-10):844-7. PubMed ID: 6255698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy.
    Dézsi L; Mészáros T; Őrfi E; Fülöp TG; Hennies M; Rosivall L; Hamar P; Szebeni J; Szénási G
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31505853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of alternate pathway complement kinetics by electron spin resonance spectroscopy.
    Hawley DA; Kleinhans FW; Biesecker JL
    Am J Clin Pathol; 1983 Jun; 79(6):673-7. PubMed ID: 6303107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schistosoma mansoni: complement and cercarial tail loss during in vitro transformation.
    Greenblatt HC; Eveland LK; Morse SI
    Exp Parasitol; 1979 Aug; 48(1):100-8. PubMed ID: 456460
    [No Abstract]   [Full Text] [Related]  

  • 6. Function of the activated fourth component of complement (C4b) in activation of C2.
    Vogt W; Hinsch B; Schmidt G; von Zabern I
    FEBS Lett; 1982 Aug; 144(2):195-8. PubMed ID: 6981526
    [No Abstract]   [Full Text] [Related]  

  • 7. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
    Cooper PD; Sim RB
    Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key role of complement activation and platelet-activating factor in exudate formation in zymosan-induced rat pleurisy.
    Imai Y; Hayashi M; Oh-ishi S
    Jpn J Pharmacol; 1991 Oct; 57(2):225-32. PubMed ID: 1812301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the mechanism of haemopoietic stem cell (CFUs) mobilization. A role of the complement system.
    Wilschut IJ; Erkens-Versluis ME; Ploemacher RE; Benner R; Vos O
    Cell Tissue Kinet; 1979 May; 12(3):299-311. PubMed ID: 476778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble and particulate activators of complement and granulomatous pulmonary reactions.
    Pearson DJ; Green FH; Mentnech SM
    Clin Allergy; 1981 Mar; 11(2):111-9. PubMed ID: 6972274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro inhibition of the classical pathway of human complement by polymyxin B.
    Asghar SS; Boot T; van der Helm HJ
    Biochem Pharmacol; 1987 Sep; 36(18):2927-30. PubMed ID: 2820426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes.
    Van Dijk H; Rademaker PM; Willers JM
    J Immunol Methods; 1980; 36(1):29-39. PubMed ID: 7204994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemolysis of normal human erythrocytes by autologous serum complement.
    Kitamura H; Nagano A; Kitano E
    Int Arch Allergy Immunol; 1993; 100(3):209-14. PubMed ID: 8453307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of toxic oxygen intermediates to complement-induced reductions in effective hepatic blood flow.
    Schirmer WJ; Schirmer JM; Naff GB; Fry DE
    J Trauma; 1988 Sep; 28(9):1295-300. PubMed ID: 2843655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triggering of interferon gamma-primed macrophages by various known complement activators for nonspecific tumor cytotoxicity.
    Leu RW; Herriott MJ
    Cell Immunol; 1987 Apr; 106(1):114-21. PubMed ID: 3105895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of complement components on the size and the opsonization of DNA-anti-DNA complexes.
    Lamers MC; De Groot ER; Daha MR; Roos D
    Scand J Immunol; 1982 Nov; 16(5):389-401. PubMed ID: 7178842
    [No Abstract]   [Full Text] [Related]  

  • 19. Complement system in coronary heart disease: a review.
    Gardinali M; Conciato L; Cafaro C; Agostoni A
    Immunopharmacology; 1995 Aug; 30(2):105-17. PubMed ID: 8530252
    [No Abstract]   [Full Text] [Related]  

  • 20. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia.
    Jaeschke H; Farhood A; Bautista AP; Spolarics Z; Spitzer JJ
    Am J Physiol; 1993 Apr; 264(4 Pt 1):G801-9. PubMed ID: 8476062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.